H

HLB Inc
KOSDAQ:028300

Watchlist Manager
HLB Inc
KOSDAQ:028300
Watchlist
Price: 75 400 KRW 2.86% Market Closed
Market Cap: 9.9T KRW
Have any thoughts about
HLB Inc?
Write Note

HLB Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

HLB Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
H
HLB Inc
KOSDAQ:028300
Current Portion of Long-Term Debt
â‚©79.9B
CAGR 3-Years
82%
CAGR 5-Years
15%
CAGR 10-Years
58%
SD Biosensor Inc
KRX:137310
Current Portion of Long-Term Debt
â‚©136B
CAGR 3-Years
217%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
BioPlus Co Ltd
KOSDAQ:099430
Current Portion of Long-Term Debt
â‚©493.5m
CAGR 3-Years
-50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
T&L Co Ltd
KOSDAQ:340570
Current Portion of Long-Term Debt
â‚©65m
CAGR 3-Years
-2%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
H
Humasis Co Ltd
KOSDAQ:205470
Current Portion of Long-Term Debt
â‚©13.9B
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
I
Interojo Co Ltd
KOSDAQ:119610
Current Portion of Long-Term Debt
â‚©5.7B
CAGR 3-Years
93%
CAGR 5-Years
N/A
CAGR 10-Years
13%
No Stocks Found

HLB Inc
Glance View

Market Cap
9.9T KRW
Industry
Health Care

HLB Inc. is a dynamic biopharmaceutical company dedicated to the discovery and development of innovative treatments for a range of serious diseases. Founded on the principles of scientific excellence and a commitment to patient care, HLB has quickly gained recognition for its robust portfolio of drug candidates targeting areas such as oncology, autoimmune diseases, and rare disorders. The company's strategic approach combines cutting-edge research with advanced clinical trials, leveraging partnerships with leading research institutions and healthcare organizations to propel its therapeutic innovations. With a strong financial backing and a clear vision for growth, HLB is not just about developing drugs; it’s about transforming patient outcomes and making a meaningful impact on global health. As an investor, HLB Inc. presents a compelling opportunity anchored in its core strengths: a seasoned management team with a proven track record, a rich pipeline of promising drug candidates, and a robust intellectual property portfolio that secures its market position. The company’s commitment to transparency and strategic operational decisions positions it well for sustainable growth in the competitive biopharmaceutical landscape. With the increasing demand for effective therapies and advancements in medical technology, HLB stands poised to unlock significant shareholder value while driving progress in medical treatment options. This compelling narrative of potential, combined with HLB's dedication to innovation, makes it an intriguing prospect for investors seeking exposure to the biopharmaceutical sector.

Intrinsic Value
880.61 KRW
Overvaluation 99%
Intrinsic Value
Price
H

See Also

What is HLB Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
79.9B KRW

Based on the financial report for Sep 30, 2024, HLB Inc's Current Portion of Long-Term Debt amounts to 79.9B KRW.

What is HLB Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
58%

Over the last year, the Current Portion of Long-Term Debt growth was 23%. The average annual Current Portion of Long-Term Debt growth rates for HLB Inc have been 82% over the past three years , 15% over the past five years , and 58% over the past ten years .

Back to Top